These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1850 related items for PubMed ID: 10388095

  • 1. Molecular Action and Clinical Relevance of Aromatase Inhibitors.
    Murphy MJ.
    Oncologist; 1998; 3(2):129-130. PubMed ID: 10388095
    [Abstract] [Full Text] [Related]

  • 2. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS.
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [Abstract] [Full Text] [Related]

  • 3. Clinical use of aromatase inhibitors in the treatment of advanced breast cancer.
    Trunet PF, Vreeland F, Royce C, Chaudri HA, Cooper J, Bhatnagar AS.
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):241-5. PubMed ID: 9365196
    [Abstract] [Full Text] [Related]

  • 4. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M, Rody A.
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun 01; 126(2):146-54. PubMed ID: 16621229
    [Abstract] [Full Text] [Related]

  • 5. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
    Santen RJ.
    Breast Cancer Res Treat; 1986 Jun 01; 7 Suppl():S23-35. PubMed ID: 3527304
    [Abstract] [Full Text] [Related]

  • 6. Aromatase inhibitors: new endocrine treatment of breast cancer.
    Brueggemeier RW.
    Semin Reprod Med; 2004 Feb 01; 22(1):31-43. PubMed ID: 15083379
    [Abstract] [Full Text] [Related]

  • 7. Endocrine management of breast cancer.
    Schneider PG, Jackisch C, Brandt B.
    Int J Fertil Menopausal Stud; 1994 Feb 01; 39 Suppl 2():115-27. PubMed ID: 7874188
    [Abstract] [Full Text] [Related]

  • 8. Regarding: Valero V, Buzdar AU, Hortobagyi GN. "Locally Advanced Breast Cancer," The Oncologist 1996;1:8-17.
    Oliver RT.
    Oncologist; 1996 Feb 01; 1(4):278-279. PubMed ID: 10388003
    [Abstract] [Full Text] [Related]

  • 9. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J.
    Clin Ther; 2005 Nov 01; 27(11):1671-84. PubMed ID: 16368441
    [Abstract] [Full Text] [Related]

  • 10. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN.
    Clin Cancer Res; 2005 Jan 15; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
    Santen RJ, Boucher AE, Santner SJ, Henderson IC, Harvey H, Lipton A.
    J Lab Clin Med; 1987 Mar 15; 109(3):278-89. PubMed ID: 3546561
    [Abstract] [Full Text] [Related]

  • 12. [Aromatase inhibitors--new possibilities in treatment of breast carcinoma].
    Friedrichs K, Jänicke F.
    Praxis (Bern 1994); 1998 Apr 22; 87(17):584-8. PubMed ID: 9623325
    [Abstract] [Full Text] [Related]

  • 13. [Current status and prospectives of aromatase inhibitors in the treatment of advanced breast cancer].
    Boccardo F.
    Minerva Ginecol; 1998 Mar 22; 50(3):51-63. PubMed ID: 9595916
    [Abstract] [Full Text] [Related]

  • 14. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH, Johnson JR, Li N, Chen G, Pazdur R.
    Clin Cancer Res; 2002 Mar 22; 8(3):665-9. PubMed ID: 11895893
    [Abstract] [Full Text] [Related]

  • 15. The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
    Monnier AM.
    Expert Rev Anticancer Ther; 2007 May 22; 7(5):627-34. PubMed ID: 17492927
    [Abstract] [Full Text] [Related]

  • 16. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
    Winer EP, Hudis C, Burstein HJ, Wolff AC, Pritchard KI, Ingle JN, Chlebowski RT, Gelber R, Edge SB, Gralow J, Cobleigh MA, Mamounas EP, Goldstein LJ, Whelan TJ, Powles TJ, Bryant J, Perkins C, Perotti J, Braun S, Langer AS, Browman GP, Somerfield MR.
    J Clin Oncol; 2005 Jan 20; 23(3):619-29. PubMed ID: 15545664
    [Abstract] [Full Text] [Related]

  • 17. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H, Namba K.
    Kekkaku; 2006 Dec 20; 81(12):753-74. PubMed ID: 17240921
    [Abstract] [Full Text] [Related]

  • 18. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
    Monnier A.
    Expert Rev Anticancer Ther; 2006 Oct 20; 6(10):1355-9. PubMed ID: 17069521
    [Abstract] [Full Text] [Related]

  • 19. Aromatase inhibitors: rationale for use following antiestrogen therapy.
    Yue W, Santen RJ.
    Semin Oncol; 1996 Aug 20; 23(4 Suppl 9):21-7. PubMed ID: 8824461
    [Abstract] [Full Text] [Related]

  • 20. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT, Robert NJ.
    Eur J Cancer; 2005 Aug 20; 41(12):1678-89. PubMed ID: 16098456
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 93.